Highlight: BRCA1 and BRCA2 proteins in breast cancer

Microscopy Research and Technique

Volumn 59, Issue 1, 2002, Pages 68-83

  Daniel, Dianne C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

BRCT domain; Cell cycle checkpoint; Chromatin remodeling; DNA damage response; DNA repair; E3 ligase; RING finger; Tumor suppressor; Ubiquitination

Indexed keywords

DISEASES; DNA; REPAIR; TRANSCRIPTION; TUMORS;

BRCT DOMAIN; CELL CYCLE; CELL CYCLE CHECKPOINT; CHROMATIN REMODELLING; DNA DAMAGE RESPONSE; DNA-REPAIR; E3 LIGASE; RING FINGER; TUMOUR SUPPRESSOR; UBIQUITINATION;

PROTEINS;

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; LIGASE;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL CYCLE; DNA DAMAGE; DNA REPAIR; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0036786821     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.10178     Document Type: Article

References (253)

1. Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT. 1999. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 274:18808-18812.
2. Agarwal ML, Agarwal A, Taylor WR, Stark GR. 1995. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92:8493-8497.
3. Altiok S, Batt D, Altiok N, Papautsky A, Downward J, Roberts TM, Avraham H. 1999. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. J Biol Chem 274:32274-32278.
4. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. 1998. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 19:254-256.
5. Ang P, Garber JE. 2001. Genetic susceptibility for breast cancer-risk assessment and counseling. Semin Oncol 28:419-433.
6. Aprelikova ON, Fang BS, Meissner EG, Cotter S, Campbell M, Kuthiala A, Bessho M, Jensen RA, Liu ET. 1999. BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci USA 96:11866-18671.
7. Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, Aaronson SA, Lee SW. 2000. Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol 20:7450-7459.
8. Baer R. 2001. With the ends in sight: images from the BRCA1 tumor suppressor. Nat Struct Biol 8:822-824.
9. Baer R, Ludwig T. 2002. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 12:86-91.
10. Barr SM, Johnson EM. 2001. Ras-induced colony formation and anchorage-independent growth inhibited by elevated expression of Puralpha in NIH3T3 cells. J Cell Biochem 81:621-638.
11. Benson FE, Baumann P, West SC. 1998. Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature 391:401-404.
12. Bertwistle D, Swift S, Marston NJ, Jackson LE, Crossland S, Crompton MR, Marshall CJ, Ashworth A. 1997. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res 57:5485-5488.
13. Bieche I, Nogues C, Lidereau R. 1999. Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene 18:5232-5238.
14. Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F, Shiekhattar R. 2000. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102:257-265.
15. Brenton JD, Aparicio SA, Caldas C. 2001. Molecular profiling of breast cancer: portraits but not physiognomy. Breast Cancer Res 3:77-80.
16. Brown AL, Lee CH, Schwarz JK, Mitiku N, Piwnica-Worms H, Chung JH. 1999. A human Cds 1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. Proc Natl Acad Sci USA 96:3745-3750.
17. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE. 2001. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 8:833-837.
18. Buermeyer AB, Deschenes SM, Baker SM, Liskay RM. 1999. Mammalian DNA mismatch repair. Annu Rev Genet 33:533-564.
19. Buschmann T, Lerner D, Lee CG, Ronai Z. 2001. The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9. J Biol Chem 276:40389-40395.
20. Cardoso MC, Leonhardt H, Nadal-Ginard B. 1993. Reversal of terminal differentiation and control of DNA replication: cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell 74:979-992.
21. Catteau A, Harris WH, Xu CF, Solomon E. 1999. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18:1957-1965.
22. WAF1/CIP1 promoter. Oncogene 18:263-268.
23. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. 2000. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 14:1584-1588.
24. Chapman MS, Verma IM. 1996. Transcriptional activation by BRCA1. Nature 382:678-679.
25. Chappuis PO, Rosenblatt J, Foulkes WD. 1999. The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 10:1163-1170.
26. Chappuis PO, Kapusta L, Begin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD. 2000a. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 18:4045-4052.
27. Chappuis PO, Nethercot V, Foulkes WD. 2000b. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18:287-295.
28. Chen J. 2000. Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res 60:5037-5039.
29. Chen Y, Chen P-L, Riley DJ, Lee W-H, Allred DC, Osborne CK. 1996a. Location of BRCA1 in human breast and ovarian cancer cells. Technical Comments. Science 272:125-126.
30. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH. 1996b. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 56:3168-3172 (erratum, Cancer Res 1996 56:4074).
31. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R. 1998a. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2:317-328.
32. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. 1998b. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci USA 95:5287-5292.
33. Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B, Cong F, Goff SP, Wu Y, Arlinghaus R, Baltimore D, Gasser PJ, Park MS, Sung P, Lee EY. 1999a. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 274:12748-12752.
34. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG Jr. 1999b. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 96:4325-4329.
35. Choi YH. 2001. Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells. Int J Oncol 19:687-693.
36. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF, Stratton MR. 1995. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10:1673-1675.
37. Collins N, Wooster R, Stratton MR. 1997. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 76:1150-1156.
38. Cortez D, Wang Y, Qin J, Elledge SJ. 1999. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks (see Comments). Science 286:1162-1166.
39. Costanzo V, Robertson K, Bibikova M, Kim E, Grieco D, Gottesman M, Carroll D, Gautier J. 2001. Mre11 protein complex prevents double-strand break accumulation during chromosomal DNA replication. Mol Cell 8:137-147.
40. Cressman VL, Backlund DC, Avrutskaya AV, Leadon SA, Godfrey V, Koller BH. 1999. Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. Mol Cell Biol 19:7061-7075.
41. Daniel DC. 1999. Dual immunofluorescence labeling with cell-specific markers localizes BRCA1 in both basal and luminal epithelial cells in primary outgrowth from noncancerous mammary ductal and alveolar preparations. Cell Tissue Res 298:481-487.
42. Daniel DC, Weston A. 1997. Benzo(a)pyrene enhances levels of ErbB2 in normal mammary epithelial cells in organoid culture. In: Bradlow HL, Fishman J, Osborne MP, editors. Cancer: genetics and the environment. Ann NY Acad Sci 833:169.
43. Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, West SC. 2001. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7:273-282.
44. de la Serna IL, Roy K, Carlson KA, Imbalzano AN. 2001. MyoD can induce cell cycle arrest but not muscle differentiation in the presence of dominant negative SWI/SNF chromatin remodeling enzymes. J Biol Chem 276:41486-41491.
45. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. 1997. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 94:7245-7250.
46. Deng CX, Brodie SG. 2000. Roles of BRCA1 and its interacting proteins. Bioessays 22:728-737.
47. Deng CX, Scott F. 2000. Role of the tumor suppressor gene Brcal in genetic stability and mammary gland tumor formation. Oncogene 19:1059-1064.
48. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. 1999. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399:491-496.
49. DiRenzo J, Shang Y, Phelan M, Sif S, Myers M, Kingston R, Brown M. 2000. BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol 20:7541-7549.
50. Dobrovic A, Simpfendorfer D. 1997. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57:3347-3350.
51. Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Crabtree GR, Goff SP. 1994. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79:119-130.
52. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. 2001. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95:255-259.
53. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174.
54. Elliott B, Jasin M. 2001. Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. Mol Cell Biol 21:2671-2682.
55. Ellisen LW, Haber DA. 1998. Hereditary breast cancer. Annu Rev Med 49:425-436.
56. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J. 2002. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 30:290-294.
57. Fan S, Ma YX, Wang JA, Yuan RQ, Meng Q, Cao Y, Laterra JJ, Goldberg ID, Rosen EM. 2000. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase. Oncogene 19:2212-2223.
58. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM. 2002a. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 62:141-151.
59. Fan W, Jin S, Tong T, Chao H, Fan F, Antinore MJ, Rajasekaran B, Wu M, Zhan Q. 2002b. BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J Biol Chem 3:3.
60. Fang L, Li G, Liu G, Lee SW, Aaronson SA. 2001. p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 20:1931-1939.
61. Flores-Rozas H, Kelman Z, Dean FB, Pan ZQ, Harper JW, Elledge SJ, O'Donnell M, Hurwitz J. 1994. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci USA 91:8655-8659.
62. Freemont PS. 2000. RING for destruction? Curr Biol 10:R84-87.
63. Fuks F, Milner J, Kouzarides T. 1998. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17:2531-2534.
64. Futamura M, Arakawa H, Matsuda K, Katagiri T, Saji S, Miki Y, Nakamura Y. 2000. Potential role of BRCA2 in a mitotic checkpoint after phosphorylation by hBUBR1. Cancer Res 60:1531-1535.
65. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Söderkvist P, Terry L. Jhanwar S, Berchuck A, Iglehart JD, Marks J, Balligner DG, Barrett JC, Skolnick MH, Kamb A, Wiseman R, et al. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122.
66. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD. 2001. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249-262.
67. Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, Khanna KK. 2000. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res 60:3299-3304.
68. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. 1998. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281:1009-1012.
69. Gradia S, Subramanian D, Wilson T, Acharya S, Makhov A, Griffith J, Fishel R. 1999. hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA. Mol Cell 3:255-261.
70. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. 2001. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984.
71. Gudas JM, Nguyen H, Li T, Cowan KH. 1995. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 55:4561-4565.
72. Haber JE. 1998. The many interfaces of Mre11. Cell 95:583-586.
73. Haber JE. 1999. DNA recombination: the replication connection. Trends Biochem Sci 24:271-275.
74. Haber JE. 2000. Recombination: a frank view of exchanges and vice versa. Curr Opin Cell Biol 12:286-292.
75. Haile DT, Parvin JD. 1999. Activation of transcription in vitro by the BRCA1 carboxyl-terminal domain. J Biol Chem 274:2113-2117.
76. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689.
77. Harari D, Yarden Y. 2000. Molecular mechanisms underlying ErbB2/ HER2 action in breast cancer. Oncogene 19:6102-6114.
78. Harbour JW, Dean DC. 2000. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2:E65-67.
79. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA. 1999. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97:575-586.
80. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. 2001. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276:14537-14540.
81. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J. 2001. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548.
82. Hicke L. 2001. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2:195-201.
83. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S, Lu X. 1999. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3:181-193.
84. Hulka BS, Moorman PG. 2001. Breast cancer: hormones and other risk factors. Maturitas 38:103-116.
85. Husain A, He G, Venkatraman ES, Spriggs DR. 1998. BRCA1 upregulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58:1120-1123.
86. Ingvarsson S. 1999. The Brca1 and Brca2 proteins and tumor pathogenesis. Anticancer Res 19:2853-2861.
87. Irminger-Finger I, Soriano JV, Vaudan G, Montesano R, Sappino AP. 1998. In vitro repression of Brcal-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells. J Cell Biol 143:1329-1339.
88. Itoh H, Wortman MJ, Kanovsky M, Uson RR, Gordon RE, Alfano N, Johnson EM. 1998. Alterations in Pur(alpha) levels and intracellular localization in the CV-1 cell cycle. Cell Growth Differ 9:651-665.
89. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher FJ 3rd. 1998. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097-1112.
90. Jin Y, Xu XL, Yang MC, Wei F, Ayi TC, Bowcock AM, Baer R. 1997. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc Natl Acad Sci USA 94:12075-12080.
91. Jin S, Zhao H, Fan F, Blanck P, Fan W, Colchagie AB, Fornace AJ Jr, Zhan Q. 2000. BRCA1 activation of the GADD45 promoter. Oncogene 19:4050-4057.
92. Johnson EM, Allfrey VG. 1978. Postsynthetic modifications of histone primary structure: phosphorylation and acetylation as related to chromatin conformation and function. In: Litwack G, editor. Biochemical actions of hormones. New York: Academic Press, vol. V. p 1-51.
93. Johnson RD, Jasin M. 2000. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J 19:3398-3407.
94. Johnson RE, Kovvali GK, Guzder SN, Amin NS, Holm C, Habraken Y, Sung P, Prakash L, Prakash S. 1996. Evidence for involvement of yeast proliferating cell nuclear antigen in DNA mismatch repair. J Biol Chem 271:27987-27990.
95. Johnstone RW, Ruefli AA, Lowe SW. 2002. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164.
96. Karp SE. 2000. Clinical management of BRCA1- and BRCA2-associated breast cancer. Semin Surg Oncol 18:296-304.
97. Karran P. 2000. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 10:144-150.
98. Kelman Z, Hurwitz J. 1998. Protein-PCNA interactions: a DNA-scanning mechanism? Trends Biochem Sci 23:236-238.
99. Kerr P, Ashworth A. 2001. New complexities for BRCA1 and BRCA2. Curr Biol 11:R668-676.
100. Khanna KK, Jackson SP. 2001. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247-254.
101. Khavari PA, Peterson CL, Tamkun JW, Mendel DB, Crabtree GR. 1993. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription. Nature 366:170-174.
102. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B. 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251-2256.
103. Kleiman FE, Manley JL. 2001. The BARD1-CstF-50 interaction links mRNA 3′ end formation to DNA damage and tumor suppression. Cell 104:743-753.
104. Kovalenko OV, Plug AW, Haaf T, Gonda DK, Ashley T, Ward DC, Radding CM, Golub EI. 1996. Mammalian ubiquitin-conjugating enzyme Ubc9 interacts with Rad51 recombination protein and localizes in synaptonemal complexes. Proc Natl Acad Sci USA 93:2958-2963.
105. Lakhani SR. 2001. Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. Mol Pathol 54:281-284.
106. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA. 1996. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13:238-240.
107. Larner JM, Lee H, Little RD, Dijkwel PA, Schildkraut CL, Hamlin JL. 1999. Radiation down-regulates replication origin activity throughout the S phase in mammalian cells. Nucleic Acids Res 27:803-809.
108. Le Page F, Randrianarison V, Marot D, Cabannes J, Perricaudet M, Feunteun J, Sarasin A. 2000. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 60:5548-5552.
109. Lee H, Trainer AH, Friedman LS, Thistlethwaite FC, Evans MJ, Ponder BA, Venkitaraman AR. 1999a. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell 4:1-10.
110. Lee WY, Jin YT, Chang TW, Lin PW, Su IJ. 1999b. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. Histopathology 34:106-112.
111. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. 2000. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404:201-204.
112. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, Giangrande P, Wu L, Saavedra HI, Field SJ, Thompson MA, Yang H, Fujiwara Y, Greenberg ME, Orkin S, Smith C, Nevins JR. 2001. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 8:105-113.
113. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
114. Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, Yarden Y. 2000. c-Cbl is a suppressor of the neu oncogene. J Biol Chem 275:35532-35539.
115. Li S, Chen PL, Subramanian T, Chinnadurai G, Tomlinson G, Osborne CK, Sharp ZD, Lee WH. 1999. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem 274:11334-11338.
116. Li S, Ting NS, Zheng L, Chen PL, Ziv Y, Shiloh Y, Lee EY, Lee WH. 2000a. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 406:210-215.
117. Li W, Hesabi B, Babbo A, Pacione C, Liu J, Chen DJ, Nickoloff JA, Shen Z. 2000b. Regulation of double-strand break-induced mammalian homologous recombination by UBL1, a RAD51-interacting protein. Nucleic Acids Res 28:1145-1153.
118. Lim DS, Kirsch DG, Canman CE, Ahn JH, Ziv Y, Newman LS, Darnell RB, Shiloh Y, Kastan MB. 1998. ATM binds to beta-adaptin in cytoplasmic vesicles. Proc Natl Acad Sci USA 95:10146-10151.
119. Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH, Kastan MB. 2000. ATM phosphorylates p95/nbsl in an S-phase checkpoint pathway. Nature 404:613-617.
120. Lin WC, Lin FT, Nevins JR. 2001. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15:1833-1844.
121. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ. 2000. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448-1459.
122. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. 1999. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 96:11364-11369.
123. MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, Muschel RJ, Cowan KH, El-Deiry WS. 2000. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 275:2777-2785.
124. Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W, Archer TK. 1998. CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 16:1161-1169.
125. Mao Y, Desai SD, Liu LF. 2000a. SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem 275:26066-26073.
126. Mao Y, Sun M, Desai SD, Liu LF. 2000b. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci USA 97:4046-4051.
127. Maor SB, Abramovitch S, Erdos MR, Brody LC, Werner H. 2000. BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab 69:130-136.
128. Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD. 1997. BRCA1 expression is not directly responsive to estrogen. Oncogene 14:115-121.
129. Marmorstein LY, Ouchi T, Aaronson SA. 1998. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 95:13869-13874.
130. Marmorstein LY, Kinev AV, Chan GK, Bochar DA, Beniya H, Epstein JA, Yen TJ, Shiekhattar R. 2001. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Cell 104:247-257.
131. Maser RS, Mirzoeva OK, Wells J, Olivares H, Williams BR, Zinkel RA, Farnham PJ, Petrini JH. 2001. Mrell complex and DNA replication: linkage to E2F and sites of DNA synthesis. Mol Cell Biol 21:6006-6016.
132. Matsuoka S, Huang M, Elledge SJ. 1998. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893-1897.
133. Melchior F, Hengst L. 2000. Mdm2-SUMO1: is bigger better? Nat Cell Biol 2:E161-163.
134. Meloni AR, Smith EJ, Nevins JR. 1999. A mechanism for Rb/p130- mediated transcription repression involving recruitment of the CtBP corepressor. Proc Natl Acad Sci USA 96:9574-9579.
135. Mielnicki LM, Asch HL, Asch BB. 2001. Genes, chromatin, and breast cancer: an epigenetic tale. J Mammary Gland Biol Neoplasia 6:169-182.
136. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, CannonAlbright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71.
137. Milner J, Fuks F, Hughes-Davies L, Kouzarides T. 2000. The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase. Oncogene 19:4441-4445.
138. Mirzoeva OK, Petrini JH. 2001. DNA damage-dependent nuclear dynamics of the Mrell complex. Mol Cell Biol 21:281-288.
139. Mitsui A, Sharp PA. 1999. Ubiquitination of RNA polymerase II large subunit signaled by phosphorylation of carboxyl-terminal domain. Proc Natl Acad Sci USA 96:6054-6059.
140. Monteiro AN. 2000. BRCA1: exploring the links to transcription. Trends Biochem Sci 25:469-474.
141. Monteiro AN, August A, Hanafusa H. 1996. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93:13595-13599.
142. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371:72-74.
143. Moynahan ME, Chiu JW, Koller BH, Jasin M. 1999. Brca1 controls homology-directed DNA repair. Mol Cell 4:511-518.
144. Moynahan ME, Pierce AJ, Jasin M. 2001. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7:263-272.
145. Muchardt C, Yaniv M. 2001. When the SWI/SNF complex remodels⋯the cell cycle. Oncogene 20:3067-3075.
146. Müller S, Hoege C, Pyrowolakis G, Jentsch S. 2001. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2:202-210.
147. Nathanson KL, Wooster R, Weber BL. 2001. Breast cancer genetics: what we know and what we need. Nat Med 7:552-556.
148. Neuhausen SL, Marshall CJ. 1994. Loss ofheterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res 54:6069-6072.
149. Nevins JR. 2001. The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703.
150. O'Brien KA, Lemke SJ, Cocke KS, Rao RN, Beckmann RP. 1999. Casein kinase 2 binds to and phosphorylates BRCA1. Biochem Biophys Res Commun 260:658-664.
151. Ortolan TG, Tongaonkar P, Lambertson D, Chen L, Schauber C, Madura K. 2000. The DNA repair protein rad23 is a negative regulator of multi-ubiquitin chain assembly. Nat Cell Biol 2:601-608.
152. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. 1998. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95:2302-2306.
153. Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM. 2000. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc Natl Acad Sci USA 97:5208-5213.
154. Ozcelik H, To MD, Couture J, Bull SB, Andrulis IL. 1998. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int J Cancer 77:1-6.
155. Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM. 2000. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97:1020-1025.
156. Parvin JD. 2001. BRCA1 at a branch point. Proc Natl Acad Sci USA 98:5952-5954.
157. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR. 1998. Involvement of Brca2 in DNA repair. Mol Cell 1:347-357.
158. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. 2000. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10:886-895.
159. Paull TT, Cortez D, Bowers B, Elledge SJ, Gellert M. 2001. From the Cover: Direct DNA binding by Brcal. Proc Natl Acad Sci USA 98:6086-6091.
160. Pegram MD, Konecny G, Slamon DJ. 2000. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103:57-75.
161. Pham AD, Sauer F. 2000. Ubiquitin-activating/conjugating activity of TAFII250, a mediator of activation of gene expression in Drosophila. Science 289:2357-2360.
162. Phillips KA. 2000. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107S-112S.
163. Phillips KA, Andrulis IL, Goodwin PJ. 1999. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol 17:3653-3663.
164. Pickart CM. 2001. Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533.
165. Prives C. 1998. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:5-8.
166. Rahman N, Stratton MR. 1998. The genetics of breast cancer susceptibility. Annu Rev Genet 32:95-121.
167. Ratner JN, Balasubramanian B, Corden J, Warren SL, Bregman DB. 1998. Ultraviolet radiation-induced ubiquitination and proteasomal degradation of the large subunit of RNA polymerase II. Implications for transcription-coupled DNA repair. J Biol Chem 273:5184-5189.
168. Rice JC, Futscher BW. 2000. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res 28:3233-3239.
169. Rice JC, Massey-Brown KS, Futscher BW. 1998. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17:1807-1812.
170. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. 1998. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858-5868.
171. Rogakou EP, Boon C, Redon C, Bonner WM. 1999. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146:905-916.
172. Ruffner H, Verma IM. 1997. BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci USA 94:7138-7143.
173. Ruffner H, Jiang W, Craig AG, Hunter T, Verma IM. 1999. BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol 19:4843-4854.
174. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. 2001. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 98:5134-5139.
175. Schauber C, Chen L, Tongaonkar P, Vega I, Lambertson D, Potts W, Madura K. 1998. Rad23 links DNA repair to the ubiquitin/proteasome pathway. Nature 391:715-718.
176. Scully R. 2001. Interactions between BRCA proteins and DNA structure. Exp Cell Res 264:67-73.
177. Scully R, Livingston DM. 2000. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408:429-432.
178. Scully R, Ganesan S, Brown M, DeCaprio JA, Cannistram SA, Feunteun J, Schnitt S, Livingston DM. 1996. Technical Comments: Location of BRCA1 in breast and ovarian cancer cells. Science 272:123-126.
179. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. 1997. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90:425-435.
180. Scully R, Puget N, Vlasakova K. 2000. DNA polymerase stalling, sister chromatid recombination and the BRCA genes. Oncogene 19:6176-6183.
181. Sears RC, Nevins JR. 2002. Signaling networks that link cell proliferation and cell fate. J Biol Chem 277:11617-11620.
182. Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, Nicholson RI. 1999. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 84:258-262.
183. Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux S, Khochbin S. 2001. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol 21:8035-8044.
184. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. 2000. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 183:18-27.
185. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. 1997. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810.
186. Shen Z, Pardington-Purtymun PE, Comeaux JC, Moyzis RK, Chen DJ. 1996a. Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system. Genomics 37:183-186.
187. Shen Z, Pardington-Purtymun PE, Comeaux JC, Moyzis RK, Chen DJ. 1996b. UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics 36:271-279.
188. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
189. Sherr CJ, Weber JD. 2000. The ARF/p53 pathway. Curr Opin Genet Dev 10:94-99.
190. Shiloh Y. 2001. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11:71-77.
191. Smith SA, Easton DF, Evans DG, Ponder BA. 1992. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 2:128-131.
192. Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, Koller BH. 1999. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brcal transgene. Oncogene 18:7900-7907.
193. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Wu GS, Licht JD, Weber BL, El-Deiry WS. 1997. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389:187-190.
194. Somasundaram K, MacLachlan TK, Burns TF, Sgagias M, Cowan KH, Weber BL, el-Deiry WS. 1999. BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene 18:6605-6614.
195. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
196. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM. 1999. Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci USA 96:13920-13925.
197. Spencer VA, Davie JR. 1999. Role of covalent modifications of histones in regulating gene expression. Gene 240:1-12.
198. Sterner DE, Berger SL. 2000. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64:435-459.
199. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45.
200. Tang HY, Zhao K, Pizzolato JF, Fonarev M, Langer JC, Manfredi JJ. 1998. Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53. J Biol Chem 273:29156-29163.
201. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc J-F, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon-Albright L, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE. 1996. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337.
202. Taylor WR, Stark GR. 2001. Regulation of the G2/M transition by p53. Oncogene 20:1803-1815.
203. Taylor J, Lymboura M, Pace PE, A'Hern R P, Desai AJ, Shousha S, Coombes RC, Ali S. 1998. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 79:334-342.
204. Thien CB, Walker F, Langdon WY. 2001. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol Cell 7:355-365.
205. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P. 1997. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ 8:801-809.
206. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. 1995. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444-450.
207. Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, Elledge SJ, Abraham RT. 2000. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 14:2989-3002.
208. Umar A, Buermeyer AB, Simon JA, Thomas DC, Clark AB, Liskay RM, Kunkel TA. 1996. Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis. Cell 87:65-73.
209. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
210. van de Vijver MJ. 2001. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 37(Suppl 1):11-17.
211. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD. 1996. Cell cycle control of BRCA2. Cancer Res 56:4590-4594.
212. Venkitaraman AR. 2001. Chromosome stability, DNA recombination and the BRCA2 tumour suppressor. Curr Opin Cell Biol 13:338-343.
213. Venkitaraman AR. 2002. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171-182.
214. Vousden KH. 2000. p53: death star. Cell 103:691-694.
215. Wang H, Shao N, Ding QM, Cui J, Reddy ES, Rao VN. 1997. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene 15:143-157.
216. Wang Q, Zhang H, Kajino K, Greene MI. 1998. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17:1939-1948.
217. Wang A, Schneider-Broussard R, Kumar AP, MacLeod MC, Johnson DG. 2000a. Regulation of BRCA1 expression by the Rb-E2F pathway. J Biol Chem 275:4532-4536.
218. Wang Q, Zhang H, Fishel R, Greene MI. 2000b. BRCA1 and cell signaling. Oncogene 19:6152-6158.
219. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. 2000c. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927-939.
220. Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel R, Greene MI. 2001. Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene 20:4640-4649.
221. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
222. Weissman AM. 2001. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2:169-178.
223. Welcsh PL, King MC. 2001. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713.
224. Welcsh PL, Owens KN, King MC. 2000. Insights into the functions of BRCA1 and BRCA2. Trends Genet 16:69-74.
225. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR. 2001. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98:11462-11467.
226. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. 1994. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7:480-484.
227. Williams RS, Green R, Glover JN. 2001. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8:838-842.
228. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. 1999. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21:236-240.
229. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. 1997. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 272:31941-31944.
230. Wong AKC, Ormonde PA, Pero R, Chen Y, Lian L, Salada G, Berry S, Lawrence Q, Dayananth P, Ha P, Tavtigian SV, Teng DH-F, Bartel PL. 1998. Characterization of a carboxy-terminal BRCA 1 interacting protein. Oncogene 17:2279-2285.
231. Woods DB, Vousden KH. 2001. Regulation of p53 function. Exp Cell Res 264:56-66.
232. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-2090.
233. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR. 1995. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792.
234. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. 1996. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430-440.
235. Wu K, Jiang SW, Thangaraju M, Wu G, Couch FJ. 2000. Induction of the BRCA2 promoter by nuclear factor-kappa B. J Biol Chem 275:35548-35556.
236. Wu-Baer F, Baer R. 2001. Effect of DNA damage on a BRCA1 complex. Nature 414:36.
237. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, Lu KP. 2001. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20:3459-3472.
238. Xu B, Kim S, Kastan MB. 2001. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 21:3445-3450.
239. Yap DB, Hsieh JK, Chan FS, Lu X. 1999. mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18:7681-7689.
240. Yarden RI, Brody LC. 1999. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 96:4983-4988.
241. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. 2002. BRCA1 regulates the G2/M checkpoint by activating Chk kinase upon DNA damage. Nat Genet 11:11.
242. Yu X, Baer R. 2000. Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. J Biol Chem 275:18541-18549.
243. Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R. 1998. The C- terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem 273:25388-25392.
244. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S, Wang R, Sung P, Shinohara A, Weichselbaum R, Kufe D. 1998. Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 273:3799-3802.
245. Zhang HT, Zhang X, Zhao HZ, Kajino Y, Weber BL, Davis JG, Wang Q, O'Rourke DM, Zhang HB, Kajino K, Greene MI. 1997. Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. Oncogene 14:2863-2869.
246. Zhang H, Somasundaram K, Peng Y, Tian H, Bi D, Weber BL, ElDeiry WS. 1998a. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713-1721.
247. Zhang JJ, Zhao Y, Chait BT, Lathem WW, Ritzi M, Knippers R, Darnell JE Jr. 1998b. Ser727-dependent recruitment of MCM5 by Statlalpha in IFN-gamma-induced transcriptional activation. EMBO J 17:6963-6971.
248. Zhao S, Weng YC, Yuan SS, Lin YT, Hsu HC, Lin SC, Gerbino E, Song MH, Zdzienicka MZ, Gatti RA, Shay JW, Ziv Y, Shiloh Y, Lee EY. 2000. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature 405:473-477.
249. Zheng L, Lee WH. 2001. The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp Cell Res 264:2-18.
250. Zheng L, Li S, Boyer TG, Lee WH. 2000a. Lessons learned from BRCA1 and BRCA2. Oncogene 19:6159-6175.
251. Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, Lee WH. 2000b. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 6:757-768.
252. Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH. 1999. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285:747-750.
253. Zhou BB, Elledge SJ. 2000. The DNA damage response: putting checkpoints in perspective. Nature 408:433-439.